Corbus Pharmaceuticals (CRBP) Revenue & Revenue Breakdown
Corbus Pharmaceuticals Revenue Highlights
00
Corbus Pharmaceuticals Revenue by Period
Corbus Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | -100.00% |
| 2021-12-31 | $881.71K | -77.61% |
| 2020-12-31 | $3.94M | -89.11% |
| 2019-12-31 | $36.14M | 649.51% |
| 2018-12-31 | $4.82M | 97.62% |
| 2017-12-31 | $2.44M | 27.66% |
| 2016-12-31 | $1.91M | 194.80% |
| 2015-12-31 | $648.38K | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2013-12-31 | - | - |
Corbus Pharmaceuticals generated - in revenue during NA 2023, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Corbus Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | - | 100.00% |
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $1.35M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | -100.00% |
| 2021-12-31 | $-881.71K | -1005.96% |
| 2021-09-30 | $97.32K | -28.73% |
| 2021-06-30 | $136.56K | -78.92% |
| 2021-03-31 | $647.82K | -1.58% |
| 2020-12-31 | $658.20K | -46.51% |
| 2020-09-30 | $1.23M | 329.77% |
| 2020-06-30 | $286.35K | -83.75% |
| 2020-03-31 | $1.76M | -31.53% |
| 2019-12-31 | $2.57M | -0.63% |
| 2019-09-30 | $2.59M | -91.10% |
| 2019-06-30 | $29.09M | 1442.92% |
| 2019-03-31 | $1.89M | -2.16% |
| 2018-12-31 | $1.93M | 76.67% |
| 2018-09-30 | $1.09M | 27.79% |
| 2018-06-30 | $853.65K | -10.18% |
| 2018-03-31 | $950.44K | -138.95% |
| 2017-12-31 | $-2.44M | -406.44% |
| 2017-09-30 | $796.31K | 127.40% |
| 2017-06-30 | $350.19K | -72.93% |
| 2017-03-31 | $1.29M | 244.37% |
| 2016-12-31 | $375.67K | -49.41% |
| 2016-09-30 | $742.56K | 87.23% |
| 2016-06-30 | $396.60K | - |
| 2016-03-31 | $396.60K | 8.87% |
| 2015-12-31 | $364.29K | 113.72% |
| 2015-09-30 | $170.45K | 50.00% |
| 2015-06-30 | $113.64K | 100.00% |
| 2015-03-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2014-09-30 | - | 100.00% |
| 2014-06-30 | - | 100.00% |
| 2014-03-31 | - | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2013-09-30 | - | - |
Corbus Pharmaceuticals generated - in revenue during Q3 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Corbus Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| CTMX | CytomX Therapeutics | $101.21M | $33.43M |
| SPRO | Spero Therapeutics | $96.73M | $13.47M |
| MREO | Mereo BioPharma Group | $10.00M | - |
| AFMD | Affimed | $8.28M | $155.00K |
| ASMB | Assembly Biosciences | $7.16M | $6.84M |
| CUE | Cue Biopharma | $5.49M | $3.34M |
| XFOR | X4 Pharmaceuticals | - | $560.00K |
| ANTX | AN2 Therapeutics | - | - |
| CRBP | Corbus Pharmaceuticals | - | - |
| BCAB | BioAtla | - | $11.00M |
| DAWN | Day One Biopharmaceuticals | - | $20.07M |
| ZURA | Zura Bio | - | - |
| ABOS | Acumen Pharmaceuticals | - | - |
| INZY | Inozyme Pharma | - | - |
| NXTC | NextCure | - | - |
| ELEV | Elevation Oncology | - | - |
| TRVI | Trevi Therapeutics | - | - |
| ADVM | Adverum Bio | - | - |
| ZVSA | ZyVersa Therapeutics | - | - |
| OCEA | Ocean Biomedical | - | - |
| KOD | Kodiak Sciences | - | - |
| GLMD | Galmed Pharmaceuticals | - | - |